Stock listing
Regentis Biomaterials Ltd.
Selected listing: RGNT · AMEX · USD · US
Regentis Biomaterials Ltd. (NYSE American: RGNT), Health Technology. Latest release Sep 11, 2026: Regentis Biomaterials Reports First Half 2026 Financial…
- Ticker
- NYSE American: RGNT
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NYSE American
- Currency
- USD
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. is a public company traded under the ticker RGNT in the American market. Regentis focuses on developing innovative biomaterials for medical applications.
Latest news from Regentis Biomaterials Ltd.
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
September 11, 2026
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
July 20, 2026
Regentis Biomaterials (RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
July 16, 2026
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
July 15, 2026
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
June 17, 2026
Research Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. company profile
View the public company page for Regentis Biomaterials Ltd. on 6ix.
Regentis Biomaterials Ltd. news
Read company news and market updates connected to Regentis Biomaterials Ltd..
Regentis Biomaterials Ltd. investor events
Find investor webinars, events, and replay context for Regentis Biomaterials Ltd..